Despite an increasing emphasis on the role of senior management cognition in shaping organizational action, there have been few attempts to link top management mental models to strategic choice in the face of discontinuous innovation. This paper uses 23 years of data covering 15 major pharmaceutical firms to explore the degree to which each firm's response to the revolution in biotechnology was shaped by the senior team's recognition of biotechnology's importance. Controlling for a number of important alternative explanations, we show that recognition may be an important predictor of action, suggesting that cognition at the most senior level can play a critical role in shaping established firms' response to discontinuities. Copyright 2003, Oxford University Press.
Download Info
To our knowledge, this item is not available for
download. To find whether it is available, there are three
options:
1. Check below under "Related research" whether another version of this item is available online.
2. Check on the provider's web page
whether it is in fact available.
3. Perform a search for a similarly titled item that would be
available.
Volume (Year): 12 (2003) Issue (Month): 2 (April) Pages: 203-233 Download reference. The following formats are available: HTML
(with abstract),
plain text
(with abstract),
BibTeX,
RIS (EndNote, RefMan, ProCite),
ReDIF
Contact details of provider: Postal: Oxford University Press, Great Clarendon Street, Oxford OX2 6DP, UK Fax: 01865 267 985 Email: Web page: http://icc.oupjournals.org/
For technical questions regarding this item, or to correct its listing, contact: (Christopher F. Baum).
Related research
Keywords:
Cited by: (explanations, Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.)